These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35371293)

  • 1. Factors affecting minimal manifestation status induction in myasthenia gravis.
    Li Y; Yang S; Dong X; Li Z; Peng Y; Jin W; Chen D; Zhou R; Jiang F; Yan C; Yang H
    Ther Adv Neurol Disord; 2022; 15():17562864221080520. PubMed ID: 35371293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of myasthenia gravis in elderly patients: a retrospective study.
    Li Y; Dong X; Li Z; Peng Y; Jin W; Zhou R; Jiang F; Xu L; Luo Z; Yang H
    Neurol Sci; 2022 Apr; 43(4):2775-2783. PubMed ID: 34677704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of postoperative radiotherapy in thymoma patients with myasthenia gravis.
    Chen L; Li Y; Dong X; Tanzhu G; Chu X; Deng F; Li X; Zhang J; Long B; Jing D; Niu L; Peng H; Yang H; Zhou R
    Radiother Oncol; 2023 Jun; 183():109644. PubMed ID: 36990391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
    McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
    Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.
    Duan W; Peng Y; Jin W; Ouyang S; Yang H
    J Immunol Res; 2021; 2021():9138548. PubMed ID: 34845439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis.
    Zhao C; Pu M; Chen D; Shi J; Li Z; Guo J; Zhang G
    Front Neurol; 2021; 12():736190. PubMed ID: 34721267
    [No Abstract]   [Full Text] [Related]  

  • 7. Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.
    Vemuri D; Garuda BR; Gopi S; Kumar TS; Kumari UA
    Ann Indian Acad Neurol; 2020; 23(2):215-219. PubMed ID: 32189865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
    Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
    Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
    Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJGM; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Silvestri NJ; Conwit R; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
    Lancet Neurol; 2019 Mar; 18(3):259-268. PubMed ID: 30692052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of clinical factors affecting outcome of myasthenia gravis.
    Yoshimoto Y; Ishida S; Hosokawa T; Arawaka S
    Muscle Nerve; 2021 Jul; 64(1):90-94. PubMed ID: 33885175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody profile may predict outcome in ocular myasthenia gravis.
    Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
    Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics of low frequency repetitive nerve stimulation in patients with myasthenia gravis and its correlation with clinical features].
    He XT; Wang LJ; Chen JL; Xie CG; Gan R; Yang R
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2443-2447. PubMed ID: 34399557
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of ocular symptoms in myasthenia gravis.
    Bhanushali MJ; Wuu J; Benatar M
    Neurology; 2008 Oct; 71(17):1335-41. PubMed ID: 18936425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal manifestation status and prednisone withdrawal in the MGTX trial.
    Lee I; Kuo HC; Aban IB; Cutter GR; McPherson T; Kaminski HJ; Sussman J; Ströbel P; Oger J; Cea G; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJG; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Minisman G; Sonett JR; Wolfe GI;
    Neurology; 2020 Aug; 95(6):e755-e766. PubMed ID: 32611638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.
    Fan Z; Lei L; Su S; Zhang S; Xie N; Li L; Lu Y; Di L; Wang M; Xu M; Shen XM; Da Y
    Ann Clin Transl Neurol; 2023 Apr; 10(4):589-598. PubMed ID: 36808840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete stable remission and autoantibody specificity in myasthenia gravis.
    Baggi F; Andreetta F; Maggi L; Confalonieri P; Morandi L; Salerno F; Bernasconi P; Montomoli C; Barberis M; Mantegazza R; Antozzi C
    Neurology; 2013 Jan; 80(2):188-95. PubMed ID: 23255823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of outcome measures for myasthenia gravis subgroups.
    Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
    J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.